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Trials of disease management programs pose several method-
ological challenges. Our objective is to assess the extent to which
the various development steps of a cluster randomized trial to
evaluate disease management are represented in the framework
for the design and evaluation of complex interventions. The
framework for evaluating complex interventions developed by
Campbell and colleagues is composed by ﬁve phases: theoretical,
identiﬁcation of components of the intervention, deﬁnition of
trial and intervention design, methodological issues for main
trial, and promoting effective implementation. Using these phases
the corresponding stages in the development of the cluster ran-
domized trial to evaluate the effectiveness of disease management
programs are identiﬁed and described. Synthesis of evidence
needed to construct the program, survey and qualitative research
used to deﬁne components of the program, a pilot study to assess
the feasibility of delivering the care, methodological issues in the
main trial including choice of design, allocation concealment,
outcomes, sample size calculation and analysis are adequately
represented using the stages of the framework for evaluating
complex interventions. Even though is difﬁcult to deﬁne precisely
what exactly the “active ingredients” of a program of disease
management and how they relate to each other, we think that the
applied framework is a powerful resource for researchers plan-
ning a randomized clinical trial to evaluate the effectiveness of
such programs.
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This study assesses the Rasch measurement properties of the
SF-12 version 2 (SF-12v2) physical and mental health (PH and
MH) items in respondents with most prevalent chronic condi-
tions. Medical Expenditures Panel Survey (MEPS) respondents’
age  18 with complete SF-12v2s from 2003 were extracted
(n = 19,906). Eleven subgroups were identiﬁed using the
primary ICD-9-CM code for the top 10 chronic conditions
(hypertension, diabetes, depression, back disorder, arthropathy,
cholesterol, asthma, sinusitis, anxiety and joint disorder) and
healthy persons (n = 8324). Respondents with perfect scores
demonstrating ceiling (n = 303) and ﬂoor effects (n = 12) were
removed to ensure uncertainty in the responses. Coding
reﬂected that higher scores represent healthier respondents. The
Rasch partial credit model was used to exam the item category
properties and ﬁt statistics. Residual factor analysis was con-
ducted to assess the factor loadings on the items. Item misﬁt
took place mostly among MH items (inﬁt/outﬁt z-score >2.0).
Particularly, MH item “Have you felt calm and peaceful?”
showed misﬁt across all subgroups. Rasch residual analysis
identiﬁed 75.2% to 86.9% of the shared variance within clus-
ters of all items. Further, PH items had positive factor loadings
while MH items had negative factor loadings, with few excep-
tions (3/11). Some item category steps had poor step properties.
Mental health items are more likely to be noisy. The patterns of
the factor loadings of the PH and MH items were as expected
in most of the groups suggesting that the SF-12v2 has two
distinct factors measuring the overall health. Poor item cat-
egory performance suggests that collapsing of these categories
might improve the quality of the instrument.
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OBJECTIVE: Health states deﬁned by classiﬁcation systems like
the EQ-5D can be valued using techniques that aim to elicit
cardinal measures directly, such as the time trade-off (TTO) and
visual analogue scale (VAS), but also by ranking the health states.
In this study, we estimate international value sets for the 243
EQ-5D states based on rank, TTO and VAS responses and test
their equivalence. METHODS: We estimated the coefﬁcients
scale is recommended in Sweden [in Swedish] of a conditional
logit and a linear probability model of rank responses as well as
the coefﬁcients of two linear models of TTO and VAS responses
using pooled data from eight countries: Slovenia, Argentina,
Denmark, Japan, Netherlands, Spain, UK and US, which gave us
179,431 responses from 11,483 subjects. The main difference
between the two rank models is that one models utility in
ln(odds), as suggested by McFadden, and the second in probabil-
ity. The regression speciﬁcations have previous models estimated
in the United States and UK nested within its framework. Fur-
thermore, we compare rescaled predicted values for the 242
EQ-5D states, excluding 11,111, across techniques in terms of
correlation and concordance. RESULTS: The non-optimal gap
reduces when utilities are linearly modeled in probability instead
of log-odds, as suggested by McFadden. The rank-based values
are highly correlated with both TTO and VAS values. Compared
to the log-odds model, the linear probability model produces
rank-based values with greater concordance to TTO/VAS values.
CONCLUSION: In former investigations we tested if ranking in
the large pool of data produce values of health states comparable
with direct measures as TTO and VAS. In this investigation we
provide further evidence by showing convergent validity between
TTO/VAS and alternative rank-based models for the whole valu-
ation space. This evidence emphasizes the promise of a valuation
technique that incorporates ordinal responses. Overall, rank-
based values merits closer investigation.
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OBJECTIVES: Temporary health states (states with a duration of
less than one year) are common and include many infectious
diseases, short-term treatments, and diagnostic procedures. Valu-
ation of these states requires special consideration because the
health state is transitory and standard methods ignore the inﬂu-
ence of duration on preferences. Inaccurate assessments could
introduce bias into cost-utility ratios. There is no “gold stan-
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